Previously, we evaluated the therapeutic efficacy of the adenovirus-mediated transduction of the cytosine deaminase (CD) gene and 5-fluorocytosine (5-FC) for malignant gliomas. However, the molecular pathways that mediate the 5-FC/CD gene therapy-induced cell death remains to be elucidated. In this study, we examined the induction of apoptosis and the role of caspases in 5-FC/CD gene therapy using human malignant glioma cells [Gli36 5 (mutated p53) and U87MG (wild p53)]. The treatment with 5-FC/CD gene-therapy-induced apoptosis both in Gli36 5 cells and in U87MG cells according to flow cytometric analysis. Immunoblot analysis revealed that caspases 3 and 9 were processed in response to 5-FC/CD in a concentration-and time-dependent manner, but caspase 8 was not. Each caspase 3 and 9 inhibitor significantly reduced apoptosis triggered by 5-FC/CD, but the caspase 8 inhibitor did not affect apoptosis induction. 5-FC/CD significantly promoted the release of cytochorme c from mitochondria in a concentration-dependent manner. These results indicate that 5-FC/CD gene therapy induces apoptosis in human malignant glioma cells and that the apoptotic cell death is mediated by the activation of mitochondrial caspase cascades involving caspases 3 and 9. This is the first report concerning the apoptotic mechanism of 5-FC/CD gene therapy, and these findings could be used to increase the efficacy of suicide gene therapy systems for the treatment of malignant glioma.
Introduction
Malignant gliomas are a significant cause of mortality in the adult cancer population and are responsible for ∼7% of all cancer-related deaths. The chemotherapeutic approaches presently in use have failed to make an impact on the treatment of gliomas because of significant toxicity, problems with drug delivery, and the high degree of chemoresistance demonstrated by these tumors [1] . To overcome this problem, prodrug/gene-directed enzyme therapy (suicide gene therapy) [2] [3] [4] [5] was developed. Ganciclovir (GCV)/ herpes simplex virus thymidine kinase (HSV-TK) seemed to be a good representative of suicide gene therapy [3] . However, the clinical experiences with TK/GCV therapy for glioblastoma have not fulfilled the expectations built on the experimental data [6] [7] [8] .
The transduction of the E. coli cytosine deaminase (CD) gene into tumor cells combined with the administration of 5-fluorocytosine (5-FC) is also one of the suicide gene therapies used for malignant tumors [9, 10] . Previously, we evaluated the therapeutic efficacy of adenovirus-mediated transduction of the CD gene and 5-FC for brain tumors [10] [11] [12] . However, the molecular pathways that mediate 5-FC/CD gene-therapy-induced cell death remains to be elucidated.
Apoptotic cell death is involved in regulating tissue homeostasis in numerous physiological and pathological conditions. Two pathways of caspase activation in cancer cells have been reported [13] [14] [15] [16] [17] [18] [19] . These are mitochondrial-dependent pathways and mitochondrial-independent pathways. In this study, we examined the induction of apoptosis and the role of caspases and the mitochondrial release of cytochrome c on 5-FC/CD gene therapy using human malignant glioma cells.
Materials and methods

Cell lines and recombinant adenovirus vectors
A total of 293 cells (transformed human embryonic kidney cells; JCRB9068, Health Science Research Resources Bank, Osaka, Japan) and human malignant glioma cells [Gli36 5 (mutated p53) and U87MG (wild p53), a generous gift from E.A. Chiocca] were grown in Dulbecco's modified Eagle's medium (Invitrogen Corp., Carlsbad, CA) supplemented with 10% fetal bovine serum, 40 U/ml penicillin G, and 100 µg/ml streptomycin. The cells were maintained at 37
• C in a humidified atmosphere of 5% CO 2 . Two recombinant replication-deficient adenovirus vectors, AdexCALacZ and AdexCACD, were constructed from a serotype 5 wild-type adenovirus (Ad5) by inserting the chicken alphaglobin promoter (CA) driving the E. coli LacZ gene or the E. coli CD gene into the E1 region of the genome. These adenoviruses also had a deleted E3 region. The recombinant adenovirus vector AdexCALacZ and AdexCACD were prepared according to a method described previously [10] [11] [12] . Viral stocks were produced by infecting the 293 cells with recombinant adenovirus and were purified by CsCl density-gradient centrifugation. They were then dialyzed against phosphate-buffered saline (PBS) containing 10% glycerol, and stored at −80
• C. The viral titer was determined with an endpoint cytopathic effect assay of the 293 cells and expressed as plaque-forming units (PFU) per milliliter [20] .
5-FC chemosensitivity
To show that transduction of the CD gene sensitizes cells to 5-FC, human glioma cells were seeded in a 96-well microtiter plate at a density of 1000 cells/well and infected with AdexCACD at an multiplicity of infection (MOI) of 0-10. Twenty-four hours after the initial incubation, medium containing 5-FC was added at various concentrations for another 96 h or at fixed concentrations for different lengths of times. The percentage of surviving cells was determined to evaluate drug chemosensitivity. The cells were incubated for 1.5 h with the mitochondrial substrate 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1) (Roshe, Mannheim, Germany). The optical density of each well was measured at 650 nm with a microplate spectrophotometer. The experiment was repeated at least three times.
APOBRDU assay
DNA fragments in apoptotic cells were detected by using the APO-BRDU kit (Phoenix Flow Systems, Inc., San Diego, CA) according to the manufacturer's instructions. The 3 -hydroxyl ends of the DNA in apoptotic cells were labeled with bromodeoxyuridine triphosphate nucleotides (Br-dUTP) by terminal deoxynucleotidyl transferase, and Br-dUTP was stained with a fluorescein isothiocyanate (FITC)-labeled antibromodeoxyuridine monoclonal antibody. Samples were stained with propidium iodide and analyzed by FACScan. Hyperploid cells were excluded by gating in the FACS analysis [21] . Seventy-two hours later, the percentage of apoptotic cells was assessed with this assay.
Immunoblot analysis
With immunoblot analysis, we examined whether the treatment with 5-FC/CD gene-therapy-induced caspase activation via the mitochondrial pathway. The cell monolayer was rinsed twice with ice-cold PBS and collected by scraping. The floating cells were also added for the extraction. Immunoblot analysis was performed with an ECL-plus kit (Amersham, Buckinghamshire, England), as Shinoura et al. [21] , described. In brief, 1.0 × 10 6 cells were lysed by incubating them for 15 min on ice in a lysis buffer (10 mM Tris-HCl [pH 8.0], 0.2% Nonidet P-40 [NP-40], 1 mM EDTA), and the protein assay kit (Bio-Rad, Hercules, CA) was used according to the manufacturer's instructions. An equal volume of 2× Laemmli buffer was added to the supernatant, and this solution was boiled for 5 min. Equal amounts of protein from each extract (20 µg per lane) were separated on 10% polyacrylamide gels and transferred onto nitrocellulose membranes. After blocking with 5% dry milk in Tween-PBS (PBS containing 0.1% Tween 20), the membranes were incubated with the primary antibodies for 1 h or overnight at 4
• C. The membranes were later washed with Tween-PBS and incubated with the second antibody at 25
• C. Staining was carried out by using the ECL-plus kit.
The following primary mouse monoclonal antibodies were used: anti-human caspase 8 (1 : 1000; Cell signaling technology, Beverly, MA, USA), cytochrome c (2 µg/ml; Pharmingen, San Diego, CA, USA), and β-actin (1 : 1000; Biomol research laboratories, Plymouth Meeting, PA, USA). The following primary rabbit polyclonal antibodies were used: anti-human caspase 3 (1 : 1000; Pharmingen), and antihuman caspase 9 (1 : 1000; Cell signaling technology). The specific antibody binding the primary mouse monoclonal antibodies or the primary rabbit polyclonal antibodies was detected by anti-mouse IgG antibodylinked horseradish peroxidase (Amersham) or antirabbit IgG-linked horseradish peroxidase (Amersham), respectively.
Measurement of cytochrome c release
After the cells were treated as indicated, they were washed with PBS and lysed in lysis buffer (10 mM Tris-HCL [pH 8.0], 0.2% Nonidet P-40 [NP-40], 1 mM EDTA). After 10 min on ice, the nuclei were pelleted by centrifugation for 10 min at 750 × g and resuspended in the lysis buffer. The supernatant fluids were centrifuged again at 10,000 × g for 20 min. The cytosolic fraction (supernatant fluid) was then transferred to new tubes [19] .
Caspase inhibition assay
To further study whether caspases 3, 8 and 9 are involved in the signal transduction of 5-FC/CD gene therapy, we carried out annexin V staining to detect the early stage of cell apoptosis, as described [20] . Cells were seeded in 6-cm culture dishes (1 × 10 5 cells per dish) and were infected with AdexCACD at MOIs of 0-10. Twenty-four hours after the initial incubation, the cells were preincubated for 1 h with caspase 3, 8 or 9 inhibitor made soluble in DMSO. After an additional 48-h incubation with 5-FC, cells were washed with PBS and stained with annexin V (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Percentages of annexin V-positive cells were analyzed by flow cytometry.
The following caspase inhibitors were used:
Data analysis
All data are expressed as the mean ± SD. Statistical significance was assessed with 1-way ANOVA using statistical software (Statview, SAS Institute Inc., NC, USA). A level of p < 0.05 was considered statistically significant.
Results
Chemosensitivity
The first experiments were designed to establish 5-FC/CD-induced cell death in two characterized glioma cell lines, Gli36 5 and U87MG (Figure 1 ). In Gli36 5 cells infected with AdexCALacZ and AdexCACD at an MOI of 10, the survival rates were 74.1% and 35.2% 96 h after treatment with 5FC, respectively. In U87MG cells infected with AdexCALacZ and AdexCACD at a MOI of 5, the survival rates were 77.9% and 35.1% 96 h after treatment with 5FC, respectively. These cells became sensitive to 5-FC after CD gene transfer in a concentration-and time-dependent manner.
5-FC/CD gene-therapy-induced apoptosis
We investigated whether the treatment with 5-FC/CD gene-therapy-induced apoptosis in human malignant glioma cells by flow cytometric analysis using the APO-BRDU kit. Figure 2 shows the results of flow cytometric analysis. The percentage of apoptotis in the control cells was 1.2% in Gli36 5 cells and 3.5% in U87MG cells. 5-FC/CD treatment induced apoptosis in 69.4% of attached Gli36 5 cells (Figure 2A ) and in 68.8% of attached U87MG cells ( Figure 2B ) infected with AdexCACD at MOIs of 10 and 2, respectively.
Caspase activation and cytochrome c release
The next series of experiments was designed to examine whether the treatment with 5-FC/CD gene-therapy-induced caspase activation via the mitochondrial pathway. Caspase activation was analyzed by using the immunoblot assay (Figure 3) . Caspase 3 is produced as a 32 kDa proenzyme and cleaved into 17 kDa. In Gli36 5 cells and U87MG infected with AdexCACD at MOIs of 10 or 2, 5-FC treatment induced the activation form of caspase 3 ( Figure 3A ). Caspase 9 is produced as a 48 kDa proenzyme and cleaved into two sizes 37 and 35 kDa, of active enzymes. In Gli36 5 cells and U87MG cells infected with AdexCACD at MOIs of 10 and 2, 5-FC treatment induced the activation form of caspase 9 ( Figure 3B ). Immunoblot analysis revealed that caspases 3 and 9 were processed in both cells in response to 5-FC/CD in a concentration-and time-dependent manner. On the other hand, caspase 8 is produced as a 55 kDa proenzyme and cleaved into a 15 kDa-active enzyme. Our data showed that 5-FC/CD treatment did not induce apparent 18 kDa bans in either cell ( Figure 3C ).
On induction of apoptosis, mitochondria can release apoptogenic factors such as cytochrome c into the cytosol, which may directly activate downstream effector caspases, such as caspases 3 and 9. Therefore, we investigated the cytochrome c release after 5-FC/CD gene therapy. Figure 4 shows that 5-FC/CD promoted the release of cytochrome c from mitochondria in a concentration-dependent manner in both Gli36 5 cells and U87MG cells exposed for 72 h to 5-FC. This suggests that the mitochondrial pathway contributes to 5-FC/CD-triggered apoptosis by releasing cytochrome c into the cytosol.
Inhibition of apoptosis by caspases 3 and 9
To further study whether caspases 3, 8 and 9 are involved in the signal transduction of 5-FC/CD gene therapy, we used inhibitors of these caspases. The inhibitors used were those with the greatest inhibitory concentration. The final concentration of caspase inhibitor was the most inhibitory, as follows: for Gli36 5, the concentration of 50 µM of each inhibitor, and for U87MG, the concentration of 10 µM of each inhibitor. In Gli36 5 cells, 5-FC/CD treatment induced 41% apoptotic cells. Caspases 3 and 9 inhibitors partially suppressed apoptotic cells to 29% and 30% (p < 0.05), but the caspase 8 inhibitor did not affect the induction of apoptosis (38%) ( Figure 5A ). In U87MG cells, the result was the same. In the control cells of U87MG, 5-FC/CD treatment induced 40% apoptotic cells. Caspases 3 and 9 inhibitors decreased the induction of apoptosis to 23% and 21%, respectively (p < 0.05). But the caspase 8 inhibitor did not influence apoptotic induction (37%) ( Figure 5B ). We repeated the procedure using a higher concentration of caspase 8 inhibitor, but the result was the same. Caspases 3 and 9 inhibitors significantly reduced the apoptosis triggered by 5-FC/CD treatment, but the caspase 8 inhibitor did not affect apoptosis induction.
Discussion
The first trial of experimental therapy for malignancy using 5-FC/CD was described by Nishiyama et al. [22] . They implanted a CD capsule into the tumor bed. This capsule converted systemically administered nontoxic 5-FC to highly toxic 5-FU to obtain a high local concentration of 5-FU and to minimize systemic toxicity. To achieve high and stable enzyme activity in tumor cells, Mullen et al. [9] , applied gene transfer methodologies to this system. 5-FC/CD gene therapy with an adenovirus vector has been used to treat solid tumors, including colorectal [23, 24] , gastric [18] , and hepatocellular cancer [25] , and gliomas [26] . Recently, we evaluated the therapeutic efficacy and neurotoxicity of adenovirus-mediated transduction of the CD gene and 5-FC for experimental malignant brain tumors in rats [10] . We also reported that the coexpression of CD and UPRT genes could generate a synergistic antitumor effect on experimental brain tumors in rats [11, 12] . Although previous studies demonstrated the efficacy and side effects of 5-FC/CD gene therapy, the mechanism of tumor cell death is unknown. For further study, we needed to analyze the profound molecular mechanism of this therapy.
Two pathways of caspase activation in cancer cells have generally been reported in cell death [13] [14] [15] [16] [17] .
These are mitochondrial-independent pathways and mitochondrial-dependent pathways. The first pathway involves the ligation of death receptors by their ligands. When an apoptotic stimulus (e.g. Fas ligand) induces the oligomerization of Fas, the activated receptor recruits the adaptor molecule Fas-associating protein with a death domain [27, 28] . The death effector domain binds to the corresponding peptide motif within the prodomain of caspase 8, thereby recruiting caspase 8 to a death-inducing signaling complex (DISC) with the Fas-associated death domain protein [29] [30] [31] . The activated caspase 8 then acts to cleave and activate the downstream caspase 3 [14, 15] . Recently, it has been reported that caspase 8 cleaves Bid, a Bcl-2-interacting protein that triggers the release of cytochorme c from the intermembrane space of the mitochondria [32] .
In the second pathway, various forms of cellular stress trigger the mitochondrial release of cytochrome c into the cytosol. This released cytochrome c binds to Apaf 1, which then binds to procaspase 9 [33, 34] . After transactivation of the complex procaspase 9 to active caspase 9, activated caspase 9 then cleaves and activates the downstream caspase 3. Caspase 3, designated as CPP32 or Apopain, has been reported to cleave the inhibitor of caspase-activated DNase (ICAD) and to inactivate its CAD-inhibitory effect. This is followed by the activation of CAD, which degrades the DNA in to small fragments ( Figure 6 ) [16, 17] . We examined the induction of apoptosis and the role of caspase cascades involving caspases 3 and 9 on 5-FC/CD gene therapy using human malignant glioma cells. Moreover, mitochondria were centrally involved in regulating 5-FC/CD-induced apoptosis.
Mitochondria play a major role in apoptosis triggered by many stimuli [35] . Glaser et al. [36] , reported that TK/GCV gene therapy triggered mitochondrial cytochrome c release, activated caspase, and then induced cell death. They demonstrated that the caspase 8 inhibitor (crm-A) had no effect on TK/GCV-induced cytotoxicity. In this study, the caspase most proximate to death receptors, caspase 8, did not play an important role in the killing pathway of 5-FC/CD since 5-FC/CD treatment did not activate caspase 8 in apoptotic cells. Furthermore, the preferential caspase 8 inhibitor (IETD-FMK) was not protective for apoptosis. On the other hand, the caspase 3 and 9 inhibitors significantly reduced the apoptosis of glioma cells induced by 5-FC/CD treatment. 5-FC/CD therapy activates the mitochondrial apoptotic pathway in glioma cells, as evidenced by the detection of mitochondrial cyotochrome c release and the processing of multiple caspases. Prominent and early caspase 9 processing was compatible with the mitochondrial triggering of the caspase cascade, as reported previously [37] . Kuwana et al. [38] , demonstrated that the mitochondria-dependent pathway was more efficient than the mitochondria-independent pathway in the event of apoptosis. Therefore, as in our study, the direct effect on mitochondria may lead to early apoptosis and, consequently, greater cell death. However, some investigators have reported that both caspases 3 and 8 played a role in apoptotic induction by 5-FU (active enzyme of 5-FC) in colorectal adenocarcinoma cells [39] . The role of caspase 8 is complicated in apoptosis induced by 5-FC/CD treatment.
We used two types of glioma cells, wild and mutated p53 cells, to analyze the relationship between p53 and caspase induction. Both cells became sensitive to 5-FC after CD gene transfer. Furthermore, the apoptotic cell death was mediated by activating mitochondrial caspase cascades involving caspases 3 and 9. Therefore, no differences were observed between wild and mutated p53 cells in the apoptotic pathways downstream of the mitochondrial activation. Several reports have described the apoptotic pathways upstream of the mitochondria. In general, if p53 is wild type, DNA damage activates p53. Then, active p53 stimulates BAX [40] or death receptors, such as Fas [41, 42] and tumor-necrosis-factor-related apoptosis-inducing ligand receptor (TRAIL-R) [43] . If p53 is mutated type, apoptosis stimuli either inactivate Bcl-2 [44] , or activate c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) [45, 46] or death receptors [42] . Further examination of 5-FC/CD therapy in other glioma cells and the pathways upstream of mitochondria should better define the correlation between p53 and apoptosis induction.
Recent reports show that members of antiapoptotic gene families, such as the inhibitor of apoptosis (IAP) family, which are regulated by SMAC/DIABLO (second mitochondria-derived activator of caspase/direct IAP binding protein with low pI), are often up-regulated in brain tumors, where their role in blocking apoptosis contributes to tumor progression [47] [48] [49] . In particular, XIAP, HIAP-1, and HIAP-2 increase in abundance in glioma cell lines (e.g. U87MG) [49] . Further studies must focus on the relationship between IAP and caspases. Shinoura et al. [50] reported that an adenovirus vector for caspase 8 induced cell death in gliomas. They also demonstrated that the proapoptotic function induced by p53 transduction in U87MG cells was repressed at several steps and that the induction of caspase 9 might circumvent this resistance mechanism [51] . Thus, gene therapies using various apoptotic genes have been reported. Our results indicate that the apoptotic cell death is mediated by the activation of mitochondrial caspase cascades involving caspases 3 and 9. These findings may open new avenues for effective strategies (e.g. combining apoptotic gene caspase 8 with 5-FC/CD gene therapy) that target malignant brain tumors.
